Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
68Ga-FC516 + 68Ga-labeled ACP3-targeting tracer
- Development stage
- Unknown
- Lead developer
- FindCure Biosciences
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
68Ga-FC516 + 68Ga-labeled ACP3-targeting tracer is a diagnostic radiopharmaceutical combination developed by FindCure Biosciences (ZhongShan) Co., Ltd. for the imaging of prostate cancer. The regimen involves the use of 68Ga-FC516, an investigational PET tracer, alongside a 68Ga-labeled tracer that targets Prostatic Acid Phosphatase (ACP3, also known as PAP). ACP3 is a glycoprotein enzyme produced by the prostate and is significantly overexpressed in prostate cancer cells, serving as a specific biomarker for the disease. This dual-tracer approach is utilized in clinical studies to evaluate and compare the diagnostic performance, safety, and biodistribution of the novel FC516 agent against ACP3-targeted and PSMA-targeted imaging, facilitating improved detection and characterization of prostate malignancies via PET/CT.
- Other names
- 68Ga-FC516 + 68Ga-labeled PAP-targeting tracer68Ga-FC516 + 68Ga-labeled Prostatic Acid Phosphatase-targeting tracer
02
Targets
PAP (Prostatic acid phosphatase)
Beyond the preview
Go deeper on 68Ga-FC516 + 68Ga-labeled ACP3-targeting tracer.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 68Ga-FC516 + 68Ga-labeled ACP3-targeting tracer.